Late-Season Influenza Vaccine Effectiveness Against Medically Attended Outpatient Illness, United States, December 2022–April 2023

Jessie R Chung; Philip Shirk; Manjusha Gaglani; Manohar B Mutnal; Mary Patricia Nowalk; Krissy Moehling Geffel; Stacey L House; Tara Curley; Karen J Wernli; Erika L Kiniry; Emily T Martin; Ivana A Vaughn; Vel Murugan; Efrem S Lim; Elie Saade; Kiran Faryar; Olivia L Williams; Emmanuel B Walter; Ashley M Price; John R Barnes; Juliana DaSilva; Rebecca Kondor; Sascha Ellington; Brendan Flannery

doi:10.1111/irv.13342

Late-Season Influenza Vaccine Effectiveness Against Medically Attended Outpatient Illness, United States, December 2022–April 2023

Jessie R Chung, Philip Shirk, Manjusha Gaglani, Manohar B Mutnal, Mary Patricia Nowalk, Krissy Moehling Geffel, Stacey L House, Tara Curley, Karen J Wernli, Erika L Kiniry, Emily T Martin, Ivana A Vaughn, Vel Murugan, Efrem S Lim, Elie Saade, Kiran Faryar, Olivia L Williams, Emmanuel B Walter, Ashley M Price, John R BarnesJuliana DaSilva, Rebecca Kondor, Sascha Ellington, Brendan Flannery

Research output: Contribution to journal › Article › peer-review

Abstract

Background: The 2022–23 US influenza season peaked early in fall 2022. Methods: Late-season influenza vaccine effectiveness (VE) against outpatient, laboratory-confirmed influenza was calculated among participants of the US Influenza VE Network using a test-negative design. Results: Of 2561 participants enrolled from December 12, 2022 to April 30, 2023, 91 laboratory-confirmed influenza cases primarily had A(H1N1)pdm09 (6B.1A.5a.2a.1) or A(H3N2) (3C.2a1b.2a.2b). Overall, VE was 30% (95% confidence interval −9%, 54%); low late-season activity precluded estimation for most subgroups. Conclusions: 2022–23 late-season outpatient influenza VE was not statistically significant. Genomic characterization may improve the identification of influenza viruses that circulate postinfluenza peak.

Original language	English
Article number	e13342
Journal	Influenza and other Respiratory Viruses
Volume	18
Issue number	6
DOIs	https://doi.org/10.1111/irv.13342
State	Published - Jun 2024

Keywords

influenza
vaccination
vaccine effectiveness

Access to Document

10.1111/irv.13342

Cite this

Chung, JR., Shirk, P., Gaglani, M., Mutnal, MB., Nowalk, MP., Moehling Geffel, K., House, SL., Curley, T., Wernli, KJ., Kiniry, EL., Martin, ET., Vaughn, IA., Murugan, V., Lim, ES., Saade, E., Faryar, K., Williams, OL., Walter, EB., Price, AM., ... Flannery, B. (2024). Late-Season Influenza Vaccine Effectiveness Against Medically Attended Outpatient Illness, United States, December 2022–April 2023. Influenza and other Respiratory Viruses, 18(6), Article e13342. https://doi.org/10.1111/irv.13342

@article{e2d8db018ad84ea891d71aa34525dae8,

title = "Late-Season Influenza Vaccine Effectiveness Against Medically Attended Outpatient Illness, United States, December 2022–April 2023",

abstract = "Background: The 2022–23 US influenza season peaked early in fall 2022. Methods: Late-season influenza vaccine effectiveness (VE) against outpatient, laboratory-confirmed influenza was calculated among participants of the US Influenza VE Network using a test-negative design. Results: Of 2561 participants enrolled from December 12, 2022 to April 30, 2023, 91 laboratory-confirmed influenza cases primarily had A(H1N1)pdm09 (6B.1A.5a.2a.1) or A(H3N2) (3C.2a1b.2a.2b). Overall, VE was 30% (95% confidence interval −9%, 54%); low late-season activity precluded estimation for most subgroups. Conclusions: 2022–23 late-season outpatient influenza VE was not statistically significant. Genomic characterization may improve the identification of influenza viruses that circulate postinfluenza peak.",

keywords = "influenza, vaccination, vaccine effectiveness",

author = "Jessie R Chung and Philip Shirk and Manjusha Gaglani and Manohar B Mutnal and Mary Patricia Nowalk and Krissy Moehling Geffel and Stacey L House and Tara Curley and Karen J Wernli and Erika L Kiniry and Emily T Martin and Ivana A Vaughn and Vel Murugan and Efrem S Lim and Elie Saade and Kiran Faryar and Olivia L Williams and Emmanuel B Walter and Ashley M Price and John R Barnes and Juliana DaSilva and Rebecca Kondor and Sascha Ellington and Brendan Flannery",

note = "Publisher Copyright: {\textcopyright} 2024 The Author(s). Influenza and Other Respiratory Viruses published by John Wiley & Sons Ltd.",

year = "2024",

month = jun,

doi = "10.1111/irv.13342",

language = "English",

volume = "18",

journal = "Influenza and other Respiratory Viruses",

issn = "1750-2640",

number = "6",

}

Chung, JR, Shirk, P, Gaglani, M, Mutnal, MB, Nowalk, MP, Moehling Geffel, K, House, SL, Curley, T, Wernli, KJ, Kiniry, EL, Martin, ET, Vaughn, IA, Murugan, V, Lim, ES, Saade, E, Faryar, K, Williams, OL, Walter, EB, Price, AM, Barnes, JR, DaSilva, J, Kondor, R, Ellington, S & Flannery, B 2024, 'Late-Season Influenza Vaccine Effectiveness Against Medically Attended Outpatient Illness, United States, December 2022–April 2023', Influenza and other Respiratory Viruses, vol. 18, no. 6, e13342. https://doi.org/10.1111/irv.13342

TY - JOUR

T1 - Late-Season Influenza Vaccine Effectiveness Against Medically Attended Outpatient Illness, United States, December 2022–April 2023

AU - Chung, Jessie R

AU - Shirk, Philip

AU - Gaglani, Manjusha

AU - Mutnal, Manohar B

AU - Nowalk, Mary Patricia

AU - Moehling Geffel, Krissy

AU - House, Stacey L

AU - Curley, Tara

AU - Wernli, Karen J

AU - Kiniry, Erika L

AU - Martin, Emily T

AU - Vaughn, Ivana A

AU - Murugan, Vel

AU - Lim, Efrem S

AU - Saade, Elie

AU - Faryar, Kiran

AU - Williams, Olivia L

AU - Walter, Emmanuel B

AU - Price, Ashley M

AU - Barnes, John R

AU - DaSilva, Juliana

AU - Kondor, Rebecca

AU - Ellington, Sascha

AU - Flannery, Brendan

PY - 2024/6

Y1 - 2024/6

N2 - Background: The 2022–23 US influenza season peaked early in fall 2022. Methods: Late-season influenza vaccine effectiveness (VE) against outpatient, laboratory-confirmed influenza was calculated among participants of the US Influenza VE Network using a test-negative design. Results: Of 2561 participants enrolled from December 12, 2022 to April 30, 2023, 91 laboratory-confirmed influenza cases primarily had A(H1N1)pdm09 (6B.1A.5a.2a.1) or A(H3N2) (3C.2a1b.2a.2b). Overall, VE was 30% (95% confidence interval −9%, 54%); low late-season activity precluded estimation for most subgroups. Conclusions: 2022–23 late-season outpatient influenza VE was not statistically significant. Genomic characterization may improve the identification of influenza viruses that circulate postinfluenza peak.

AB - Background: The 2022–23 US influenza season peaked early in fall 2022. Methods: Late-season influenza vaccine effectiveness (VE) against outpatient, laboratory-confirmed influenza was calculated among participants of the US Influenza VE Network using a test-negative design. Results: Of 2561 participants enrolled from December 12, 2022 to April 30, 2023, 91 laboratory-confirmed influenza cases primarily had A(H1N1)pdm09 (6B.1A.5a.2a.1) or A(H3N2) (3C.2a1b.2a.2b). Overall, VE was 30% (95% confidence interval −9%, 54%); low late-season activity precluded estimation for most subgroups. Conclusions: 2022–23 late-season outpatient influenza VE was not statistically significant. Genomic characterization may improve the identification of influenza viruses that circulate postinfluenza peak.

KW - influenza

KW - vaccination

KW - vaccine effectiveness

UR - http://www.scopus.com/inward/record.url?scp=85196672280&partnerID=8YFLogxK

U2 - 10.1111/irv.13342

DO - 10.1111/irv.13342

M3 - Article

C2 - 38923314

AN - SCOPUS:85196672280

SN - 1750-2640

VL - 18

JO - Influenza and other Respiratory Viruses

JF - Influenza and other Respiratory Viruses

IS - 6

M1 - e13342

ER -

Late-Season Influenza Vaccine Effectiveness Against Medically Attended Outpatient Illness, United States, December 2022–April 2023

Abstract

Keywords

Access to Document

Other files and links

Fingerprint

Cite this